Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.51 |
| ▸ | ITGAV | P06756 | 8/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 9/20 | 0.50 |
| ▸ | MC5R | P33032 | 9/20 | 0.50 |
| ▸ | MC3R | P41968 | 9/20 | 0.50 |
| ▸ | MC1R | Q01726 | 9/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24285403 | 0.94 | ITGB3 (0.53) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL22807688 | 0.94 | ITGB3 (0.53) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL22758169 | 0.94 | ITGB3 (0.53) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL20754200 | 0.94 | ITGB3 (0.53) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL7744260 | 0.92 | ITGB3 (0.56) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL19981446 | 0.92 | ITGB3 (0.56) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL7743670 | 0.92 | ITGB3 (0.56) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL22970321 | 0.92 | ITGB3 (0.56) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL21401905 | 0.91 | MC4R (0.50) | ITGB3ITGAVITGA5ITGB1MC4R | |
| SCHEMBL22807638 | 0.90 | ITGB3 (0.54) | ITGB3ITGAVITGA5ITGB1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191843-B2 | Multi-arm targeting anti-cancer conjugate | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-12-07 | — | — | US | disclosed |
| US-20210008218-A1 | MULTI-ARM TARGETING ANTI-CANCER CONJUGATE | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008218-A1 | MULTI-ARM TARGETING ANTI-CANCER CONJUGATE | DCLRE1A, RRP12, LARP1 | ITGB3 1461/4885ITGAV 282/4885ITGA5 1281/4885 |
| US-11191843-B2 | Multi-arm targeting anti-cancer conjugate | LCP1, RRP12, PHLPP1 | ITGB3 1642/4885ITGAV 370/4885ITGA5 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.